Viridian Announces Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 In Patients With Thyroid Eye Disease
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 20 mg/kg VRDN-001, generally consistent with 10 mg/kg results at week 6 -
- Global Phase 3 THRIVE clinical program initiated
